S&P 500   0.67 (+1.82%)
DOW   0.67 (+1.82%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.67 (+1.82%)
DOW   0.67 (+1.82%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.67 (+1.82%)
DOW   0.67 (+1.82%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.67 (+1.82%)
DOW   0.67 (+1.82%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
Log in

NASDAQ:STOKStoke Therapeutics Stock Price, Forecast & News

$28.08
-0.11 (-0.39 %)
(As of 08/12/2020 04:00 PM ET)
Add
Compare
Today's Range
$27.45
Now: $28.08
$29.22
50-Day Range
$23.02
MA: $25.10
$29.27
52-Week Range
$15.82
Now: $28.08
$39.04
Volume84,600 shs
Average Volume173,200 shs
Market Capitalization$932.73 million
P/E RatioN/A
Dividend YieldN/A
Beta0.2
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001, to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc. has a partnership with Invitae Corporation to offer epilepsy panel testing. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was founded in 2014 and is headquartered in Bedford, Massachusetts.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.46 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:STOK
CUSIPN/A
CIKN/A
Phone781-430-8200

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$6.86 per share

Profitability

Net Income$-32,330,000.00

Miscellaneous

Employees44
Market Cap$932.73 million
Next Earnings Date11/10/2020 (Estimated)
OptionableNot Optionable
$28.08
-0.11 (-0.39 %)
(As of 08/12/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive STOK News and Ratings via Email

Sign-up to receive the latest news and ratings for STOK and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Stoke Therapeutics (NASDAQ:STOK) Frequently Asked Questions

How has Stoke Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Stoke Therapeutics' stock was trading at $19.73 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, STOK stock has increased by 42.3% and is now trading at $28.08.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Stoke Therapeutics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stoke Therapeutics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Stoke Therapeutics
.

When is Stoke Therapeutics' next earnings date?

Stoke Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Stoke Therapeutics
.

How were Stoke Therapeutics' earnings last quarter?

Stoke Therapeutics (NASDAQ:STOK) released its quarterly earnings results on Monday, August, 10th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.35) by $0.04.
View Stoke Therapeutics' earnings history
.

What price target have analysts set for STOK?

6 brokerages have issued 1 year price targets for Stoke Therapeutics' stock. Their forecasts range from $30.00 to $46.00. On average, they expect Stoke Therapeutics' stock price to reach $36.80 in the next twelve months. This suggests a possible upside of 31.1% from the stock's current price.
View analysts' price targets for Stoke Therapeutics
.

Has Stoke Therapeutics been receiving favorable news coverage?

News coverage about STOK stock has trended very negative recently, InfoTrie Sentiment reports. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Stoke Therapeutics earned a media sentiment score of -3.9 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next few days.
View the latest news about Stoke Therapeutics
.

Are investors shorting Stoke Therapeutics?

Stoke Therapeutics saw a increase in short interest in February. As of February 15th, there was short interest totaling 2,340,000 shares, an increase of 13.0% from the January 31st total of 2,070,000 shares. Based on an average trading volume of 158,700 shares, the days-to-cover ratio is currently 14.7 days. Currently, 15.1% of the company's stock are sold short.
View Stoke Therapeutics' Short Interest
.

Who are some of Stoke Therapeutics' key competitors?

What other stocks do shareholders of Stoke Therapeutics own?

Who are Stoke Therapeutics' key executives?

Stoke Therapeutics' management team includes the following people:
  • Dr. Edward M. Kaye, CEO & Director (Age 70)
  • Dr. Adrian R. Krainer, Co-Founder & Director (Age 60)
  • Ms. Isabel Aznarez, Co-Founder, VP & Head of Biology
  • Mr. Stephen J. Tulipano CPA, MBA, Chief Financial Officer (Age 60)
  • Dr. Huw M. Nash Ph.D., COO & Chief Bus. Officer (Age 52)

When did Stoke Therapeutics IPO?

(STOK) raised $100 million in an IPO on Wednesday, June 19th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Credit Suisse served as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is Stoke Therapeutics' stock symbol?

Stoke Therapeutics trades on the NASDAQ under the ticker symbol "STOK."

Who are Stoke Therapeutics' major shareholders?

Stoke Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Goldman Sachs Group Inc. (0.43%), Bank of New York Mellon Corp (0.15%), SG Americas Securities LLC (0.08%), California Public Employees Retirement System (0.07%), Swiss National Bank (0.07%) and State of Wisconsin Investment Board (0.06%). Company insiders that own Stoke Therapeutics stock include Apple Tree Partners Iv, LP, Barry Ticho, Gene Liau, Huw M Nash, Robin A Walker and Rtw Investments, Lp.
View institutional ownership trends for Stoke Therapeutics
.

Which institutional investors are selling Stoke Therapeutics stock?

STOK stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, American International Group Inc., and Ameritas Investment Partners Inc.. Company insiders that have sold Stoke Therapeutics company stock in the last year include Barry Ticho, Gene Liau, Huw M Nash, Robin A Walker, and Rtw Investments, Lp.
View insider buying and selling activity for Stoke Therapeutics
.

Which institutional investors are buying Stoke Therapeutics stock?

STOK stock was purchased by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., SG Americas Securities LLC, California Public Employees Retirement System, Swiss National Bank, State of Wisconsin Investment Board, and New York State Common Retirement Fund. Company insiders that have bought Stoke Therapeutics stock in the last two years include Apple Tree Partners Iv, LP, and Rtw Investments, Lp.
View insider buying and selling activity for Stoke Therapeutics
.

How do I buy shares of Stoke Therapeutics?

Shares of STOK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Stoke Therapeutics' stock price today?

One share of STOK stock can currently be purchased for approximately $28.08.

How big of a company is Stoke Therapeutics?

Stoke Therapeutics has a market capitalization of $932.73 million. The company earns $-32,330,000.00 in net income (profit) each year or ($1.80) on an earnings per share basis. Stoke Therapeutics employs 44 workers across the globe.

What is Stoke Therapeutics' official website?

The official website for Stoke Therapeutics is www.stoketherapeutics.com.

How can I contact Stoke Therapeutics?

Stoke Therapeutics' mailing address is 45 WIGGINS AVENUE, BEDFORD MA, 01730. The company can be reached via phone at 781-430-8200 or via email at [email protected]

This page was last updated on 8/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.